257 related articles for article (PubMed ID: 28832950)
1. Engineered T cells towards TNFRSF13C (BAFFR): a novel strategy to efficiently target B-cell acute lymphoblastic leukaemia.
Turazzi N; Fazio G; Rossi V; Rolink A; Cazzaniga G; Biondi A; Magnani CF; Biagi E
Br J Haematol; 2018 Sep; 182(6):939-943. PubMed ID: 28832950
[No Abstract] [Full Text] [Related]
2. Chimeric Antigen Receptor T-Cells for the Treatment of B-Cell Acute Lymphoblastic Leukemia.
Tomuleasa C; Fuji S; Berce C; Onaciu A; Chira S; Petrushev B; Micu WT; Moisoiu V; Osan C; Constantinescu C; Pasca S; Jurj A; Pop L; Berindan-Neagoe I; Dima D; Kitano S
Front Immunol; 2018; 9():239. PubMed ID: 29515572
[TBL] [Abstract][Full Text] [Related]
3. A BAFF ligand-based CAR-T cell targeting three receptors and multiple B cell cancers.
Wong DP; Roy NK; Zhang K; Anukanth A; Asthana A; Shirkey-Son NJ; Dunmire S; Jones BJ; Lahr WS; Webber BR; Moriarity BS; Caimi P; Parameswaran R
Nat Commun; 2022 Jan; 13(1):217. PubMed ID: 35017485
[TBL] [Abstract][Full Text] [Related]
4. Antitumor efficacy of BAFF-R targeting CAR T cells manufactured under clinic-ready conditions.
Dong Z; Cheng WA; Smith DL; Huang B; Zhang T; Chang WC; Wang X; Forman SJ; Kwak LW; Qin H
Cancer Immunol Immunother; 2020 Oct; 69(10):2139-2145. PubMed ID: 32451682
[TBL] [Abstract][Full Text] [Related]
5. CD19 directed CARs in acute lymphoblastic leukemia: state of the art and beyond.
Quintás-Cardama A
Leuk Lymphoma; 2019 May; 60(5):1346-1348. PubMed ID: 30646790
[No Abstract] [Full Text] [Related]
6. Chimeric antigen receptor T-cell therapy hits the market.
Boyer MW
Immunotherapy; 2018 Aug; 10(11):911-912. PubMed ID: 30149765
[No Abstract] [Full Text] [Related]
7. HLA-matched and HLA-haploidentical allogeneic CD19-directed chimeric antigen receptor T-cell infusions are feasible in relapsed or refractory B-cell acute lymphoblastic leukemia before hematopoietic stem cell transplantation.
Jin X; Cao Y; Wang L; Sun R; Cheng L; He X; Xiao X; Jiang Y; Li Q; Zhang H; Lu W; Lyu C; Jiang Y; Meng J; Zhao M
Leukemia; 2020 Mar; 34(3):909-913. PubMed ID: 31628429
[No Abstract] [Full Text] [Related]
8. CAR T cells targeting BAFF-R can overcome CD19 antigen loss in B cell malignancies.
Qin H; Dong Z; Wang X; Cheng WA; Wen F; Xue W; Sun H; Walter M; Wei G; Smith DL; Sun X; Fei F; Xie J; Panagopoulou TI; Chen CW; Song JY; Aldoss I; Kayembe C; Sarno L; Müschen M; Inghirami GG; Forman SJ; Kwak LW
Sci Transl Med; 2019 Sep; 11(511):. PubMed ID: 31554741
[TBL] [Abstract][Full Text] [Related]
9. CAR T-cell therapy effective in B acute lymphoblastic leukaemia.
Wang M
Lancet Oncol; 2017 Jun; 18(6):e314. PubMed ID: 28528746
[No Abstract] [Full Text] [Related]
10. Humanized CD19-specific chimeric antigen-receptor T-cells in 2 adults with newly diagnosed B-cell acute lymphoblastic leukemia.
Cao J; Cheng H; Shi M; Wang G; Chen W; Qi K; Li H; Qiao J; Zhao J; Wu Q; Zeng L; Jing G; Zheng J; Xu K
Leukemia; 2019 Nov; 33(11):2751-2753. PubMed ID: 31308471
[No Abstract] [Full Text] [Related]
11. CAR T-cells for relapsed B-cell ALL in adults.
Gilbert JA
Lancet Oncol; 2018 Mar; 19(3):e143. PubMed ID: 29429915
[No Abstract] [Full Text] [Related]
12. CAR-T Cell Therapy for Acute Lymphoblastic Leukemia: Transforming the Treatment of Relapsed and Refractory Disease.
Pehlivan KC; Duncan BB; Lee DW
Curr Hematol Malig Rep; 2018 Oct; 13(5):396-406. PubMed ID: 30120708
[TBL] [Abstract][Full Text] [Related]
13. Chimeric Antigen Receptor T-Cells: Successful Translation of the First Cell and Gene Therapy From Bench to Bedside.
Rodriguez-Cartagena LG; Bowles BS; Kurani SS; Windebank AJ; Kenderian SS; Greenberg-Worisek AJ
Clin Transl Sci; 2018 Nov; 11(6):537-539. PubMed ID: 30242965
[No Abstract] [Full Text] [Related]
14. Chimeric antigen receptor therapy for T-cell acute lymphoblastic leukemia: finally catching up with B-cell leukemia?
Beyar-Katz O; Rowe JM
Haematologica; 2024 Jun; 109(6):1631-1633. PubMed ID: 38832419
[No Abstract] [Full Text] [Related]
15. Engineered bacteria guide T cells to tumors.
Bressler EM; Wong WW
Science; 2023 Oct; 382(6667):154-155. PubMed ID: 37824642
[TBL] [Abstract][Full Text] [Related]
16. CAR T cells for infection, autoimmunity and allotransplantation.
Maldini CR; Ellis GI; Riley JL
Nat Rev Immunol; 2018 Oct; 18(10):605-616. PubMed ID: 30046149
[TBL] [Abstract][Full Text] [Related]
17. Chimeric Antigen Receptor T-Cell Therapy for the Community Oncologist.
Maus MV; Levine BL
Oncologist; 2016 May; 21(5):608-17. PubMed ID: 27009942
[TBL] [Abstract][Full Text] [Related]
18. Potent anti-leukemia activities of humanized CD19-targeted Chimeric antigen receptor T (CAR-T) cells in patients with relapsed/refractory acute lymphoblastic leukemia.
Cao J; Wang G; Cheng H; Wei C; Qi K; Sang W; Zhenyu L; Shi M; Li H; Qiao J; Pan B; Zhao J; Wu Q; Zeng L; Niu M; Jing G; Zheng J; Xu K
Am J Hematol; 2018 Jul; 93(7):851-858. PubMed ID: 29633386
[TBL] [Abstract][Full Text] [Related]
19. The severe cytokine release syndrome in phase I trials of CD19-CAR-T cell therapy: a systematic review.
Jin Z; Xiang R; Qing K; Li X; Zhang Y; Wang L; Zhu H; Mao Y; Xu Z; Li J
Ann Hematol; 2018 Aug; 97(8):1327-1335. PubMed ID: 29766234
[TBL] [Abstract][Full Text] [Related]
20. Chimeric antigen receptor-engineered cytokine-induced killer cells overcome treatment resistance of pre-B-cell acute lymphoblastic leukemia and enhance survival.
Oelsner S; Wagner J; Friede ME; Pfirrmann V; Genßler S; Rettinger E; Buchholz CJ; Pfeifer H; Schubert R; Ottmann OG; Ullrich E; Bader P; Wels WS
Int J Cancer; 2016 Oct; 139(8):1799-809. PubMed ID: 27253354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
